LONDON (Reuters) – Shire is to take a leaf out of AstraZeneca’s playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie’s $46 billion offer undervalues the business.
Flemming Ornskov, Shire’s chief executive, will update i...
Shire to set out AstraZeneca-style defence against AbbVie
No comments:
Post a Comment